Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

RAS antagonist

DRUG CLASS:

RAS antagonist

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C2 – Inclusion Criteria nivolumab + rigosertib Sensitive : C2	nivolumab + rigosertib Sensitive: C2 – Inclusion Criteria nivolumab + rigosertib Sensitive : C2
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D
PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D